Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + bortezomib + dexamethasone + lenalidomide
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A four-drug anti-myeloma combination consisting of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide. Mechanistically, it pairs an anthracycline topoisomerase II inhibitor delivered in a pegylated liposome (pegylated liposomal doxorubicin) with a proteasome inhibitor (bortezomib), an immunomodulatory agent (lenalidomide), and a corticosteroid (dexamethasone). The regimen integrates complementary cytotoxic, proteasome-inhibitory, immunomodulatory, anti-angiogenic, and anti-inflammatory effects to enhance depth and duration of responses in multiple myeloma. Clinical evidence supports subsets of these components: pegylated liposomal doxorubicin combined with bortezomib improves time to progression versus bortezomib alone in relapsed/refractory multiple myeloma; lenalidomide plus dexamethasone is established therapy; and bortezomib + lenalidomide + dexamethasone (VRd/RVd) is a standard frontline triplet. This four-drug combination is used as an intensified regimen or in clinical investigations for multiple myeloma.
- Other names
- PLD + bortezomib + dexamethasone + lenalidomide
02
Targets
GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + bortezomib + dexamethasone + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + bortezomib + dexamethasone + lenalidomide.